Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide by unknown
Brief Definitive  Report 
Fine Specificity  of Cytotoxic  T  Lymphocytes  Primed 
In Vivo Either with Virus or Synthetic  Lipopeptide 
Vaccine  or Primed  In Vitro with Peptide 
By Hansj6rg Schild, Maria Norda, Karl Deres,* Kirsten Falk, 
Olaf R6tzschke, Karl-Heinz Wiesmfiller,* G~inther Jung,* 
and  Hans-Georg  Rammensee 
From the Max-Planck-Institut  fiir Biologie, Abteilung Immungenetik; and the *Institut  fiir 
Organische Chemie, Universitiit Tiibingen, I4s  Tiibingen, Germany 
Summary 
Standard synthetic peptide preparations contain numerous peptidic byproducts in small amounts, 
which may be efficiently recognized by cytotoxic T  lymphocytes (CTL).  Recognition patterns 
of such peptide mixtures by CTL may serve as a kind of fingerprint  for CTL fine  specificity. 
Three types of H-2Db-restricted CTL were compared in this way. CTL primed in vivo either 
with A/PR/8/34 influenza virus or with a synthetic lipopeptide vaccine prepared from influenza 
nucleoprotein (NP) peptide 365-380 showed identical fine specificity. Both recognize virus-infected 
cells.  In contrast,  CTL primed in vitro with  NP 365-380 had a different fine specificity and 
they did not recognize virus-infected cells. Most significantly, the two in vivo primed CTL types 
efficiently recognized the natural viral nonapeptide NP 366-374 presented by virus-infected H-2  b 
cells,  whereas the in vitro primed  CTL failed to do so. 
V 
irus-infected cells present  viral nona-  or octapeptides, 
bound to cell surface MHC class I molecules, to cyto- 
toxic T cells (1-4). To induce such virus-specific CTL, in vivo 
priming  is usually required.  A  recent report indicates  that 
CTL against viral peptides can also be induced in vitro, and 
that such in vitro primed CTL are generally not able to lyse 
virus-infected target cells (5). This failure was ascribed to the 
low affinity of CTL primed in vitro as opposed to those primed 
in vivo. The peptide used (nucleoprotein [NP] 365-380) was 
longer than  that  presented naturally by virus-infected 1-1-2  b 
cells,  which is NP 366-374.  Using the  same long peptide 
(NP 365-380), coupled to a lipophilic anchor molecule con- 
taining  three fatty acids  (the lipotripeptide  tripalmitoyl-S- 
glyceryl-cysteinyl-seryl-serine [P3CSS]  [6]),  for immuniza- 
tion in vivo, we found that the resulting CTL were readily 
able to recognize influenza virus-infected cells (7). These CTL 
were as efficient as those primed with virus in vivo. The differ- 
ence in the ability of CTL primed with virus or P3CSS-NP 
365-380 in vivo and those primed with NP 365-380 peptide 
in vitro prompted us to compare the fine specificity of the 
three different types of CTL by testing recognition  of the 
numerous peptidic byproducts present in standard synthetic 
peptide preparations  (3). 
Materials and Methods 
Virus Preparations and Mice.  C57BL/6J (B6; 1-1-2  b) mice were 
bred and maintained at the animal facility of Max-Planck-Institut 
fOr Biologie. Strain A/PR/8/34 influenza virus was grown in the 
allantoic sacs of ll-d-old embryonated chicken eggs and stored as 
infectious allantoic fluid at  - 70~  Infectivity of the preparation 
was tested by determining  the titer  of hemagglutinating  units 
(HAU; reference 8). 
Synthetic Peptides  and HPLC.  Peptides  according to A/PK/8/34 
influenza virus nucleoprotein amino acid residues 365-380 (NP 365- 
380; IASNENMETMESSTLE;  reference 2) or NP 366-374 (AS- 
NENMETM) and the lipopeptide P3CSS-NP 365-380 were syn- 
thesized and analyzed as described (3, 6, 7). Crude synthetic pep- 
tide preparations were separated by reversed phase HPLC using a 
SuperpacPep S column (Pharmacia LKB Biology Inc., Piscataway, 
NJ) as described (3). Individual fractions were collected, dried, dis- 
solved in PBS, and used for CTL assays. 
CTL  Lines and Assays.  All  CTL  lines were  established by 
stimulating  spleen cells with antigen for 5 d in 10 ml of ot-MEM 
medium supplemented with 10% FCS, B-mercaptoethanol, r-glu- 
tamine, and antibiotics, followed  by weekly restimulating CTL with 
irradiated (33 Gy) syngeneic spleen cells plus antigen in the above 
medium additionally containing Con A-induced spleen cell super- 
natant  as a source of IL-2. For the line 19C90, a B6 mouse was 
immunized  with 50 HAU of PR8 virus intravenously. 7 d later, 
2  x  107 recipient spleen cells were stimulated in vitro with virus. 
Emerging CTL were stimulated weekly with virus. The line 28B90 
was also derived from a mouse immunized in vivo with PK8 virus 
intravenously. The line 14C90 was derived from a mouse immunized 
in vivo with 100 gg P3CSS-NP 365-380 lipopeptide intravenously. 
In both latter cases, recipient splenocytes were stimulated and re- 
stimulated in vitro with 1 gg/ml NP 365-380 peptide. The lines 
29E90 and Hajo were derived from 4  x  107 splenocytes of un- 
primed mice stimulated with 1 gg/ml of NP 365-380 peptide, fol- 
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were performed  as described  (3,  7).  E/T  ratios  ranged from 8:1 
to 24:1;  spontaneous release of target cells between 8.8 and 12.8%. 
Results 
CTL  Lines.  Three types  of CTL lines are investigated 
in this study. The first type, exemplified by 19C90, is a virus- 
specific CTL line produced in the traditional way by priming 
a mouse  (B6)  with  PR8  influenza  virus,  and  stimulating 
splenocytes with virus  in vitro. If prepared from 1-1-2  b mice, 
such CTL predominantly recognize an epitope contained in 
NP 365-380  (of influenza nudeoprotein)  and are restricted 
to D b (2). A variant of this first type is the CTL line 28890, 
also derived  from a virus-primed mouse, but stimulated in 
vitro with NP 365-380  peptide.  The second type of CTL 
(14C90)  was derived  from a mouse primed in vivo with a 
novel synthetic peptide vaccine (7), consisting of a lipotripep- 
tide (P3CSS)  covalently linked to NP 365-380.  Splenocytes 
of this mouse were stimulated in vitro with NP 365-380 pep- 
tide. Both CTL types mentioned so far recognize virus-infected 
cells as well as target cells incubated with NP 365-380.  The 
third type of CTL is produced entirely in vitro: spleen cells 
from unprimed mice were stimulated and restimulated with 
NP 365-380,  as described  (5).  As exemplified by the lines 
29E90 and Hajo, this type of CTL does not recognize virus- 
infected cells, although peptide-incubated target cells are readily 
recognized (see below), confirming earlier data (5). The line 
29E90 has been tested to be D b restricted  and to be CD4- 
CD8 +  (not  shown). 
Reactivity of CTL with HPLC-separated  NP 365-380 Prepa- 
ration.  A  standard synthetic peptide prepared according to 
the NP 365-380  sequence was separated by reversed phase 
HPLC  (3).  The main peptide elutes  at the fraction corre- 
sponding to 41 ml elution volume.  Some additional, rather 
small OD 220 peaks representing peptidic byproducts elute 
between 30 and  50 ml (Fig.  1,  top).  The arrow in Fig.  1 
indicates  the elution behavior of the nonapeptide ASNEN- 
METM,  which is the only one presented by virus-infected 
cells to common Db-restricted,  nucleoprotein-specific CTL 
(3, 9). Individual fractions were tested for recognition by CTL 
at three different dilutions of fractions.  It is evident that all 
in vivo primed CTL (28B90, 14C90, and 19C90) exert a rather 
similar recognition pattern (Fig. 1). All recognize most pep- 
tide fractions at high concentrations (at dilution 1:10). Many 
distinct peptides are still recognized at the following two di- 
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Figure  1.  (Left) Fine specificity of CTL lines 28890 and 14C90. (a) Synthetic  NP 365-380 peptide was separated by reversed phase HPLC.  (__) 
Optical  density at 220 nm; (  ) percent acetonitrile in the elution gradient.  (b-d) recognition  of individual  HPLC fractions at 1:10 (b), 1:100 (c), 
and 1:1,000 (d) dilutions.  Each fraction was incubated with EL4 target cells and subsequently tested for recognition  by 28B90 CTL (Q) or by 14C90 
CTL (~7). (Right) Fine specificity of CTL lines 19C90, 29E90, and Hajo. (a) Separation of NP 365-380. (b-d) recognition  of individual HPLC fractions 
at 1:10 (b), 1:100 (c), and 1:1,000 (d) dilutions.  Each fraction was tested using  19C90 (i),  29E90 (A),  or Hajo  (O)  CTL. 
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Figure 2.  Titration experiments. Crude NP 365-380 peptide (a) or the 
fraction corresponding to 29-ml elution volume of HPLC-separated  NP 
365-380 (see Fig.  1 (b), or synthetic ASNENMETM (c) was tested in titrated 
concentrations  for  recognition by CTL  lines  28B90  (0),  141290  (~), 
29E90 (&),  or 19C90 (,).  (D) Recognition of virus-infected EL4 cells 
by three of the above CTL. 
lutions. Most notably, all three in vivo primed lines do recog- 
nize the fraction eluting at 28-29 ml with high efficiency, 
i.e., the fractions corresponding to the natural nonapeptide 
(3). The two in vitro primed CTL, 29E90 and Hajo, in con- 
trast, show a reactivity pattern distinct from the former lines. 
Their main activity appears to be directed against the bypro- 
ducts eluting between 30 and 35 ml. Even at the highest con- 
centration, both lines do not recognize any material eluting 
at 28 or 29 ml. Thus, both in vitro primed lines appear not 
to recognize ASNENMETM, which is the peptide presented 
by virus-infected cells. 
Titration Experiments.  Titrated concentrations of a crude 
16-mer peptide NP 365-380 preparation, of the fraction cor- 
responding to 29 ml elution volume (corresponding to the 
natural peptide ASNENMETM) of HPLC-separated NP 365- 
380, and of purified synthetic NP 366-374 (ASNENMETM), 
were analyzed for recognition by the three CTL types (Fig. 
2). Crude NP 365-380 is recognized by all of them. The in 
vivo primed lines 28B90 and 14C90  show no quantitative 
differences in their efficiency to recognize crude NP 365-380, 
whereas the in vitro primed line 29E90 needs "o 10-fold more 
peptide to exert the same level of lysis as the in vivo primed 
lines (Fig. 2 a). All in vivo primed CTL show identical sensi- 
tivity for the fraction at 29 ml, whereas the in vitro primed 
line does not recognize this fraction at all (Fig. 2 b). Recog- 
nition of synthetic ASNENMETM again indicates identical 
sensitivity for the in vivo lines, whereas the in vitro primed 
line needs 107-fold more of this peptide to reach the same 
level of lysis as the in vivo primed ones (Fig. 2 c). Thus, the 
relative failure to recognize the natural nucleoprotein pep- 
tide presented by Db-expressing,  PR8-infected cells appears 
to be the reason that CTL primed in vitro against free syn- 
thetic NP 365-380  peptide do not recognize virus infected 
target cells (5), as seen again in Fig. 2 d. On the other hand, 
a significant difference in fine specificity or sensitivity among 
the CTL primed in vivo with virus or with synthetic lipopep- 
tide vaccine was not observed. 
Discussion 
Our data demonstrate that influenza nucleoprotein-specific 
CTL primed in vivo with virus or with a novel synthetic 
lipopeptide vaccine on the one hand and those primed in vitro 
with synthetic free peptide on the other hand differ in their 
fine specificity. Both types of in vivo primed CTL recognize 
virus-infected cells, whereas in vitro primed CTL fail to do 
so, confirming a previous report (5). Significantly, both types 
of in vivo primed CTL, whether tested as lines or as bulk 
cultures (3, 7), efficiently recognize the naturally processed 
peptide ASNENMETM  produced by  virus-infected H-2  b 
cells, whereas the in vitro primed CTL fail to do so; they 
need 107-fold more of this nonapeptide for recognition, as 
compared with in vivo primed CTL. In contrast, both in 
vivo and in vitro primed CTL efficiently recognize a crude 
NP 365-380  peptide preparation, with only a small differ- 
ence (10-fold) in efficiency. We conclude that the failure of 
in vitro primed CTL of the kind described here (and prob- 
ably also in a previous report [5]) to recognize virus-infected 
cells is predominantly a consequence of their inability to 
efficiently recognize the naturally processed peptide presented 
by MHC molecules of virus-infected cells. In addition, a minor 
difference in the sensitivity to recognize peptide, or affinity 
of T  cells (5),  may also contribute to that failure. 
The present data strengthen the notion that peptide pu- 
rity is essential if any assay measuring T cell recognition is 
applied (3).  Accordingly, we attempted to induce in vitro 
primed CTL by using synthetic free ASNENMETM pep- 
tide,  corresponding to  the natural Db-restricted  influenza 
peptide (M.  Norda,  unpublished results).  These attempts 
failed, however, possibly due to self killing of CTL through 
this highly efficient peptide (10). 
Another practical aspect of our data is that normal syn- 
thetic peptide preparations are, in fact, complex mixtures of 
related  peptides.  Thus,  recognition of different fractions 
of HPLC-separated synthetic peptides may serve as a kind 
of "fingerprint" for CTL fine specificity. 
The different fine specificity of CTL primed in vitro with 
NP 365-380 peptide, as compared with the fine specificity 
of CTL primed in vivo with the corresponding lipopeptide 
containing the same sequence, appears to be a paradox. Since 
lipopeptides were ineffective for priming CTL in vitro (K. 
Deres, unpublished results) we are comparing here the effects 
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sible explanation for this apparent paradox is that the 16-met 
peptide coupled  to P3CSS,  by virtue  of P3CSS membrane 
affinity (11, 12), passes through cell membranes in vivo and 
joins the MHC class I-restricted  processing pathway (13), 
As a consequence, the correct natural epitope can be cut out 
of the larger peptide and can be presented by MHC mole- 
cules. In contrast, synthetic peptides, even when mixed with 
PsCSS-OH  (but  not  covalently  coupled),  may  not  enter 
cells,  and therefore are inefficient for in vivo priming  (13). 
Similarly,  a  P3CSS-lipopeptide  vaccine  induces  virus-neu- 
tralizing  antibodies,  whereas a mixture  of P3CSS-OH and 
viral peptides is nonprotective (6). Synthetic peptides in vitro, 
on the other hand,  may bind directly to cell surface class I 
molecules efficiently enough to be recognized by CTL. Since 
the processing devices of the stimulating cell are circumvented 
this way, the different fine specificity of the resulting CTL, 
as compared with in vivo primed CTL,  may be explained 
by presentation  of different peptides. 
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